The Biogenerics Market Outlook: An Analysis of Market Dynamics, Growth Drivers and Leading Players

Abstract

Branded biologic medicines generated an estimated $32bn of sales for the biotechnology and pharmaceutical industries and represented the fastest growing group of medicines; while continued high demand, high prices, and applicability in previously untreatable conditions are behind the success of branded biologics, the absence of generic competition has meant that growth has gone unchallenged. The Biogenerics Market Outlook: An analysis of market dynamics, growth drivers and leading players, is a report which examines the key drivers and resistors behind the introduction of generic biologic medicines in the European Union, United States and the rest of the world. This report provides analysis on which companies will benefit from the advent of generic biologics and identifies the companies who have the most to lose by examining the risks associated with the leading biologic brands. By 2010, biologic medicines that accrue an estimated $11.2bn worth of sales annually are expected to lose patent protection in developed pharmaceutical markets. This report identifies strategies for biogenerics success and evaluates the obstacles that need to be overcome in order to capture a share of this highly profitable, untapped market.